Autologous stem cell-derived islet tissues restored insulin function in a type 2 diabetes patient, achieving glycemic control, insulin independence, and no tumour formation over 116 weeks. This highlights the potential of stem cell therapies for advanced diabetes treatment.
April 2024 – Cell Discovery
Key takeaways
- Stem cell-derived islet tissues restoring insulin function: This breakthrough demonstrates how stem cell-derived islet tissues can re-establish normal insulin production, a significant improvement for individuals with advanced type 2 diabetes. By regaining natural glycaemic control, patients may no longer require insulin injections, improving quality of life
- No tumour formation after long-term use: Over the 116-week period, no tumours were observed, showcasing the safety of this approach. This is a vital factor when considering stem cell therapies for chronic conditions, reassuring its use in broader applications
- Improving outcomes for advanced diabetes patients: This approach holds transformative potential for those with advanced or poorly controlled diabetes, offering a therapeutic avenue that not only manages the disease but may also reverse some of its key effects, contributing to better health outcomes
Potential implications for healthspan and metabolic health: Beyond diabetes, this therapy could impact metabolic health issues linked to ageing. By improving cellular function and disease management, stem cell therapies may contribute to extended healthspan and potentially delay the onset of age-related diseases.
Read the article at: Wang, X., et al. “Treating a Type 2 Diabetic Patient with Impaired Pancreatic Islet Function by Personalized Endoderm Stem Cell-Derived Islet Tissue.” Cell Discovery, vol. 10, article no. 31, 2024, https://doi.org/10.1038/s41421-024-00662-3.
